You may not have heard of NeuStar (NYSE: NSR ) , but the services it provides can affect you greatly. This $3 billion company is also handily beating the market as it shifts its focus to move deeper into the information and analytics industry.
NeuStar started its life as an operating unit within Lockheed Martin, and won its original contract to provide local telephone number portability services in 1996. It's kept that job and performed other services along the way, including administering the registry for the .BIZ and .US Internet domain names.
After spinning off from Lockheed and notching years of success, NeuStar began to shift its focus to information and data analytics services under CEO Lisa Hook. That led to the acquisition of TARGUSinfo in 2011.
Our roving reporter Rex Moore attended the big Cable Show in Washington, D.C., and asked NeuStar's Gary Zimmerman about the company's competitive advantages.
Five stocks enter, one stock leaves
It's incredible to think just how much of our digital and technological lives are almost entirely shaped and molded by just a handful of companies. Find out "Who Will Win the War Between the 5 Biggest Tech Stocks?" in The Motley Fool's latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.
Top Energy Companies To Buy For 2015: P & F Industries Inc.(PFIN)
P&F Industries, Inc., through its subsidiaries, manufactures and sells tools and hardware products in the United States. The company operates in two segments, Tools and Other Products (Tools) and Hardware and Accessories (Hardware). The Tools segment manufactures, imports, and sells pneumatic hand tools, primarily for the industrial, retail, and automotive markets. Its product line includes sanders, grinders, drills, saws, impact wrenches, and pavement breakers; compressor air filters; and pipe and bolt dies, pipe taps, wrenches, vises and stands, pipe and tubing cutting equipment, hydrostatic test pumps, and replacement electrical components for pipe cutting and threading machines. This segment sells its products under the Florida Pneumatic, Universal Tool, ATP, Thaxton, THOR, and Eureka brand names to distributors, retailers, and private label customers through in-house sales personnel and manufacturers' representatives. The Hardware segment manufactures and imports door , window, and fencing hardware, including rollers, hinges, window operators, sash locks, custom zinc castings, and door closers. This segment also manufactures and imports interior wood and iron stair components, and related accessories, as well as kitchen and bath hardware; and manufactures stair products and distributes staircase components. Its products are sold through in-house sales personnel and manufacturers? representatives to distributors, retailers, and OEM customers. The company was founded in 1959 and is based in Melville, New York.
Advisors' Opinion:- [By Monica Gerson]
P&F Industries (NASDAQ: PFIN) is expected to report its quarterly results.
INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.
10 Best Integrated Utility Stocks To Own Right Now: Durect Corporation(DRRX)
DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical products and therapies based on its proprietary drug formulations and delivery platform technologies. The company sells ALZET osmotic pumps for animal research use; LACTEL biodegradable polymers, which are used as raw materials in pharmaceutical and medical products; and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of Remoxy, an oral oxycodone gelatin capsule for the treatment of chronic pain under approval stage with the U.S. Food and Drug Administration; POSIDUR, a Phase III clinical stage sustained-release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II clinical stage transdermal bupivacaine patch intended to provide continuous delivery of bupivacaine for up to three days from a single application for pain; and TRANSDUR, a Phase II clinical stage transdermal sufentanil patch intended to provide continuous delivery of sufentanil for up to seven days from a single application for chronic pain. The company?s Phase II clinical stage products comprise ORADUR-based opioid for the treatment of pain; and ORADUR-ADHD for the treatment of attention deficit hyperactivity disorder. It also conducts various research programs covering diseases and medical conditions of the central nervous system, cardiovascular disease, and cancer. The company has strategic agreement with Hospira, Inc.; Alpharma Ireland Limited; Nycomed Danmark ApS; Pain Therapeutics, Inc.; Pfizer Inc; Endo Pharmaceuticals Inc.; and EpiCept Corporation. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 name that's starting to move within range of triggering a major breakout trade is Durect (DRRX), which develops pharmaceutical products based on its proprietary drug delivery technology platforms. This stock is off to a hot start in 2013, with shares up sharply by 41%.
If you take a look at the chart for Durect, you'll notice that this stock has been trending sideways for the last two months and change, with shares moving between $1 on the downside and $1.34 on the upside. Shares of DRRX have now started to flirt with that $1.34 major resistance level on Thursday, since the stock has hit an intraday high of $1.35 a share with strong upside volume flows. This could be signaling that shares of DRRX are ready to break out above the upper-end of its recent range and trend substantially higher.
Traders should now look for long-biased trades in DRRX if it manages to break out above some near-term overhead resistance levels at $1.34 to $1.35 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 679,480 shares. If that breakout triggers soon, then DRRX will set up to re-fill some of its previous gap down zone from May that started near $1.80 a share. If DRRX gets into that gap with volume, then this stock could easily trend north of $2 a share.
Traders can look to buy DRRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at its 50-day moving average of $1.16 a share or its 200-day moving average at $1.11 a share. One can also buy DRRX off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
10 Best Integrated Utility Stocks To Own Right Now: Prosiebensat 1 Media AG (PSM)
ProSiebenSat 1 Media AG is a Germany-based broadcasting company. It owns commercial television stations, pay television (TV) channels and radio networks in numerous European countries. The Company operates in three business segments, including Free TV German-speaking, Free TV International and Diversification. Free TV German-speaking segment includes the stations SAT.1, ProSieben, kabel eins and sixx, as well as the sales companies SevenOneMedia and SevenOne AdFactory. Free TV International constitute of commercial TV stations in the Benelux countries and the CEE (Central and Eastern Europe) region. The Diversification segment includes all activities not directly dependent on the TV advertising market, such as call TV, music, commerce or Pay TV. Advisors' Opinion:- [By Jonathan Morgan]
RWE AG (RWE) jumped 6.4 percent, leading a gauge of utilities higher. Deutz AG (DEZ) plunged the most in more than two years after an investor sold a 8.4 percent stake in the manufacturer of diesel engines. ProSiebenSat.1 Media AG (PSM) dropped 1.1 percent after Telegraaf Media Groep NV sold its stake in the company.
10 Best Integrated Utility Stocks To Own Right Now: Medical Care Technologies Inc (MDCE)
Medical Care Technologies Inc., formerly AM Oil Resources & Technology Inc., incorporated on February 27, 2007, is a development-stage company. The Company is engaged in the development and maintenance of secure medical information systems used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company operates in three business segments: Medical Management Software Systems, Medi-Clinics and Pharmaceutical and Nutraceutical Products.
Medical Management Software Systems
The Company produces a range of medical management software systems, which could be used in a range of healthcare settings to electronically connect the healthcare industry with the consumer. It includes healthcare monitoring devices for glucose monitoring and cardiovascular monitoring and solutions, among others. The primary customers served by the software systems are hospitals and clinics, physicians��office practices, consumers and retail pharmacies, pharmaceutical companies and healthcare providers.
The Company have developed the Med-Suite Professional Practice Management information system. The Med-Suite is geared for usage by healthcare providers, such as physicians and nurses in hospitals, nursing homes and clinics. The e-management solution addresses the needs of healthcare providers to manage and communicate administrative and clinical data.
The second information systems product developed by the Company is the Tele-Health Suite. Tele-Health functions similarly to a hospital or doctor�� chart and is an interactive record to communicate patient data between healthcare providers and, healthcare providers and patients for treatment support, management and monitoring of the patient�� health.
The CareBox concept is a product designed for persons needing Tele-Health but who do not have access to the necessary computer hardware. The CareBox is a personal Internet communication de! vice that functions as the interface to the subscriber based network. The Company�� network would provide users access to telecommunication, tele-medicine applications and product access. The CareBox is engaged in the development of healthcare service delivery to the individual subscriber.
The CareBox system offers remote, real-time, audio-visual communication between patient and healthcare personnel. It offers a complete medical assessment, diagnosis, and treatment from a remote location. The CareBox processes on-site collections of physiological measurements and provides bi-directional audio-video communication.
The CareBox Bluetooth software requirements installed to mobile computing devices. It is compatible with iPhone, BlackBerry and other mobile cellular phone protocols. It enables wireless upload of personal medical information from medical and wellness monitoring devices.
Using the online facility, healthcare providers (doctors, nurses) could admit and assess patients, and subsequently create and revise individual healthcare plans. Attachments could be made to the CareBox, for monitoring blood-oxygen levels, temperature, blood pressure, pulse, as well as blood glucose levels. If readings are outside normal limits, the system would initiate a pre-programmed response and instruction for client intervention would be given. The system provides continuous monitoring at home for the clients, which serves to lengthen the period of time a person could live independently, while reducing the number of re-admissions to care facilities.
Retail Pharmacies and Retail Medical Clinics
The Company focuses to open professional, and convenience retail pharmacies and also retail medical clinics. Within the pharmacies, it focuses to have over the counter (OTC) drugs, nutritional supplements, herbal products, personal care products, family care products, as well as products, including consumable, seasonal and promotional items. The customers woul! d also ha! ve access to the medical software and hardware systems. It plans to open retail medical clinics, with a specific view to treating patients with telemedicine as well as a traditional treatment format.
Pharmaceutical and Nutraceutical Products
The Company plans to develop or source and sell pharmaceutical and nutraceutical products, and a range of other merchandise, including over-the-counter medicines, herbal products, personal care products, family care products in the planned Medi-Clinics, through the Website, retail pharmacies and through established sales and distribution channels in the People�� Republic of China. It would also offer private label products. Med-Suite, in concert with a person�� secure personal health record, would allow the medical professional to communicate pharmaceutical, administrative, clinical data in a cost-effective manner. The Company plans to use Med-Suite to provide marketing tools for pharmaceutical sales automation.
Advisors' Opinion:- [By Peter Graham]
What�� the Catch With Timios National Corp? According to various disclosures, at least one promoter expects to be compensated up to $140k to talk about Timios National Corp. However, Timios National Corp itself has been fairly quiet with news for the past several months except for financial filings. Probably the most recent relevant filing dates from September and is about an Asset Purchase Agreement with Adobe Title, LLC, whereby HOMS acquired all of the assets and properties of, and assumed certain liabilities, from the latter in consideration of $500,000 plus an earn-out equal to 7.25% of the Gross Revenue up to a maximum of $3,500,000 starting approximately six months from the date of the Agreement and ending on the forty-eighth monthly anniversary of such start date. A quick look at Timios National Corp�� financials reveals revenues of $6,810k (most recent reported quarter), $8,519k, $7,355k and $6,866k for the past four reported quarters along with a net loss of $120k (most recent reported quarter), net income of $329k and $66, and a net loss of $2,073k. At the end of September, Timios National Corp had $776k in cash to cover $3,661k in current liabilities and $6,700k in total liabilities. So its hard to explain the sudden share price decline last Friday.
Medical Care Technologies Inc (OTCMKTS: MDCE) Says Its Well Positioned to Profit From Health Care in Hong KongSmall cap Medical Care Technologies Inc, through joint ventures or Chinese subsidiaries, develops a network of family and children's health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class Chinese families. On Friday, Medical Care Technologies Inc sank 25% to $0.0012 for a market cap of $2,060 plus MDCE is up 1,100% over the past year and up 20% over the past five years according to Google Finance.
10 Best Integrated Utility Stocks To Own Right Now: StemCells Inc (STEM)
StemCells, Inc. (StemCells), incorporated in August 1988, is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�� primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�� human liver cells as a therapeutic product.
CNS Program
The Company in its CNS Program, is in clinical development with its HuCNS-SC cells for a range of disorders of the central nervous system. The CNS includes the brain, spinal cord and eye. In February 2012, the Company had completed a Phase I clinical trial in Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain.
The Company�� CNS Program is focused on developing clinical applications, in which transplanting HuCNS-SC cells protect or restore organ function of the patient before such function is irreversibly damaged or lost due to disease progression. The Company�� initial target indications are PMD, and more generally, diseases in which deficient myelination plays a central role, such as cerebral palsy or multiple sclerosis; spinal cord injury, disorders in which retinal degeneration plays a central role, such as age-related macular degeneration or retinitis pigmentosa. The Company�� product candidate, HuCNS-SC cells, is a purified and expanded composition of normal human neural stem cells. Its HuCNS-SC cells can be directly transp! lanted.
Liver Program
Liver stem or progenitor cells offer an alternative treatment for liver diseases. A liver cellular therapy or cell-based therapeutic provide or support liver function in patients with liver disease. The Company held a portfolio of issued and allowed patents in the liver field, which cover the isolation and use of both hLEC cells and the isolated subset, as well as the composition of the cells themselves.
The Company�� range of cell culture products, which are sold under the SC Proven brand, includes iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2, and NDiff N2B27. Its iSTEM is a serum-free, feeder-free medium that maintains mouse embryonic stem cells in their pluripotent ground state by using selective small molecule inhibitors to block the pathways, which induce differentiation. RHB-A is a defined, serum-free culture medium for the selective culture of human and mouse neural stem cells and their maintenance and expansion as adherent cell populations. RHB-Basal is a defined, serum-free basal medium. When supplemented with specific growth factors, this media is formulated for the propagation and differentiation of adherent neural stem cells. RHB-Basal can also be tailored to specific-cell type requirements by the addition of customer preferred supplements.
The Company�� NDiff N2 is a defined serum-free scell culture supplement for the derivation, maintenance, expansion and/or differentiation of human and mouse embryonic stem (ES) cells and tissue-derived neural stem cells supplement. Its NDiff N2-AF is a serum-free and animal component-free version of NDiff N2. Its NDiff N2B27 is a defined, serum-free medium for the differentiation of mouse embryonic stem cells to neural cell types. NDiff N27-AF is a serum-free and animal component-free version of NDiff N27. Its GS1-R is a serum-free media formulation shown to enable the derivation and long-term maintenance of true, germline competent rat embryonic stem cells without the add! ition of ! cytokines or growth factors. Its GS2-M is a defined, serum- and feeder-free medium for the derivation and long-term maintenance of true, germline competent mouse iPS cells.
The Company also markets a number of antibody reagents for use in cell detection, isolation and characterization. These reagents are also under the SC Proven brand and it includes STEM24, STEM101, STEM121 and STEM123. Its STEM24 is a human antibody that recognizes human CD24, also known as heat stable antigen (HSA), a glycoprotein expressed on the surface of many human cell types, including immature human hematopoietic cells, peripheral blood lymphocytes, erythrocytes and many human carcinomas. Its CD24 is also a marker of human neural differentiation. Its STEM101 is a human-specific mouse antibody that recognizes the Ku80 protein found in human nuclei. Its STEM121 is a human-specific mouse antibody that recognizes a cytoplasmic protein of human cells. Its STEM123 is a human-specific mouse antibody that recognizes human glial fibrillary acidic protein (GFAP).
The Company�� Other products marketed under SC Proven include total cell genomic DNA (gDNA), RNA and protein lysate reagents purified from homogenous stem cell populations for intra-comparative studies, such as Epigenetic fingerprinting, Southern, Western and Northern blots, PCR, RT-PCR and microarrays. This range of purified stem cell line lysates includes mouse embryonic stem (ES) cells propagated in SC Proven 2i inhibitor-based GS2-M media and mouse ES cell-derived and fetal tissue-derived neural stem (NS) cells propagated in SC Proven RHB-A media.
Advisors' Opinion:- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
- [By James E. Brumley]
When an investor thinks of spinal-related stem cell stocks, usually a name like Neuralstem, Inc (NYSEMKT: CUR) or StemCells Inc (NASDAQ: STEM) comes to mind. And well they should. STEM has logged some amazing breakthroughs in the field of spinal cord repair, while CUR has done the same. Not all back problems are spinal cord related though. In fact, most back problems - and therefore the most opportunity - are bone and disc related problems. That's where a young gun like BioRestorative Therapies (OTCBB: BRTX) can step in and make stem cell waves. BRTX has developed an approach to rejuvenate and revive failing spinal discs, potentially ending pain for millions of back-pain sufferers, and circumventing expensive spinal surgeries that are in increasing burden on insurance companies.
- [By John Udovich]
The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.
10 Best Integrated Utility Stocks To Own Right Now: Cott Corp (COT)
Cott Corporation (Cott), incorporated on December 31, 2006, is a producers of beverages on behalf of retailers, brand owners and distributors. The Company�� product lines include carbonated soft drinks (CSDs), 100% shelf stable juice and juice-based products, clear, still and sparkling flavored waters, energy products, sports products, new age beverages, and ready-to-drink teas, as well as alcoholic beverages for brand owners. The Company operates in five segments: North America (which includes the United States operating segment and Canada operating segment), the United Kingdom (which includes its United Kingdom reporting unit and its Continental European reporting unit), Mexico, Royal Crown International (RCI) and All Other. The Company markets or supplies over 500 retailer, licensed and Company-owned brands in its four core geographic segments. In March of 2012, its U.K. reporting segment acquired a beverage and wholesale business based in Scotland.
Advisors' Opinion:- [By Dan Caplinger]
But SodaStream is continuing to pull out all stops in order to improve its results. SodaStream's recent partnership with Samsung to incorporate carbonation technology into high-end refrigerators could help drive growth for consumers who don't want to deal with a separate appliance in their kitchens. Moreover, SodaStream's deal in March with bottler Cott (NYSE: COT ) to produce soda syrup within the U.S. should help it boost its efficiency in getting flavors to domestic customers.
- [By Nicole Seghetti]
Private-label pressures
Regardless, private labels are becoming a bigger problem for companies such as Kraft and, to a lesser extent, Mondelez. According to an industry profile compiled by First Research, these brands typically cost 20% to 40% less than name-brand products. Couple that with the fact that more consumers are ditching big brands, and we can easily see why ConAgra (NYSE: CAG ) , Cott (NYSE: COT ) , and others are continually strengthening their private-label positions.
10 Best Integrated Utility Stocks To Own Right Now: Century Aluminum Company(CENX)
Century Aluminum Company, through its subsidiaries, produces primary aluminum in the United States, China, and Iceland. The company offers high purity primary aluminum, molten aluminum, standard-grade ingots, extrusion billets, and other value-added primary aluminum products. It also holds a 40% joint venture interest in a carbon anode and cathode facility located in the Guangxi Zhuang Autonomous Region of south China. The company was founded in 1981 and is headquartered in Monterey, California.
Advisors' Opinion:- [By Travis Hoium]
What: Shares of Century Aluminum (NASDAQ: CENX ) jumped 13% today after the company announced an acquisition.
So what: The company is buying the Sebree aluminum smelter for about $61 million in cash from a subsidiary of Rio Tinto Alcan. Century will assume $71 million in working capital and won't be liable for historical environmental liabilities at the plant. �
- [By Pendulum]
Amid the challenges in the aluminum industry, Century Aluminum (CENX) has taken positive actions over the last few months. In June, it acquired the Sebree smelter in Kentucky. More importantly, it received approval for a new power contract at its Hawesville facility, which will improve its cost structure, and the company has similar plans for the new Sebree facility. These actions are reducing the company's cost of production and putting it in a better position to manage through the tough part of the aluminum price cycle. As a result of these actions, Century Aluminum's stock price has outperformed its peers. In this article, I will analyze the challenges in the aluminum industry and the positive impact of Century Aluminum's recent actions.
- [By Rich Smith]
Even as it contemplates shutting down its largest aluminum smelter in the United States, Century Aluminum (NASDAQ: CENX ) says it's planning to buy another smelter entirely. On Monday, Century announced that it's signed a definitive agreement to buy Rio Tinto's (NYSE: RIO ) Sebree aluminum smelter in Henderson County, Ky.
No comments:
Post a Comment